Copyright
©The Author(s) 2015.
World J Hypertens. May 23, 2015; 5(2): 79-84
Published online May 23, 2015. doi: 10.5494/wjh.v5.i2.79
Published online May 23, 2015. doi: 10.5494/wjh.v5.i2.79
Table 1 Trials looking at outcomes of type B dissection according to management strategy
Registry | Authors | Design | Indication | Duration | Conclusion |
Instead trial | Nienaber et al[37] | Prospective randomised trial | Comparison of TEVAR vs medical therapy in chronic type B dissection | 2 yr | TEVAR failed to improve survival or adverse events despite favourable aortic remodeling |
Instead-XL | Nienaber et al[39] | Prospective randomised trial | Long-term outcomes of cohorts recruited to INSTEAD trial | 5 yr | TEVAR plus best medical therapy improved 5-yr aorta-specific survival |
Mother registry | Patterson et al[36] | Collation of data from 5 clinical trials including VIRTUE and INSTEAD | Mid-term outcomes following endovascular repair using TEVAR for acute type B dissection | 5 yr | TEVAR provides good midterm protection from aortic-specific pathology High rates of re-intervention |
Virtue registry | The Virtue registry investigators[29] | Prospective Multicentre Clinical trial | Safety, performance and health economic data in patients receiving the Valiant endograft | 3 yr (2006-2012) | TEVAR provides protection from aortic related death in midterm High rates of re-intervention |
Adsorb trial | Hughes[10] | Multicentre randomised clinical trial | Comparison of best medical therapy vs medical therapy and TEVAR for acute type B dissection | 1 yr | TEVAR leads to improved aortic remodeling compared to medical therapy alone |
- Citation: Benson RA, Patterson BO, Loftus IM. Diagnosis and management of thoracic aortic dissection: An update. World J Hypertens 2015; 5(2): 79-84
- URL: https://www.wjgnet.com/2220-3168/full/v5/i2/79.htm
- DOI: https://dx.doi.org/10.5494/wjh.v5.i2.79